Sign up for our daily briefing

Make your busy days simpler with the Axios AM and PM newsletters. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to the Axios Closer newsletter for insights into the day’s business news and trends and why they matter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with the Axios Sports newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with the Axios Des Moines newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with the Axios Tampa Bay newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Eniola Odetunde/Axios

The quest for a universal flu vaccine in the U.S. is making "promising" progress, with the possibility of having one ready in five years.

Why it matters: Just because we're battling a coronavirus pandemic right now, doesn't mean a deadly influenza pandemic isn't waiting around the corner. Experts are aiming to create a vaccine that could target a broader array of flu strains in order to prepare for future pandemics.

"The universal flu vaccine is probably one of the most sought-after infectious disease countermeasures, because influenza has caused such a huge burden of infection every year and is very disruptive. ... And, most of our pandemic virus threats come from the influenza virus family."
— Amesh Adalja, senior scholar, Johns Hopkins Center for Health Security

Background: Currently, seasonal flu vaccines (and some treatments) are the only options available to combat influenza, which has multiple strains that can mutate quickly, killing tens of thousands of Americans every year.

  • "They're not perfect. And, in fact, they could be a lot better," says John Mascola, director of the NIH's Vaccine Research Center (VRC).
  • Because the current main method of producing these vaccines requires decisions about which strains to target to be made roughly six months prior to the season's start, their effectiveness ranges from 10% to 70% every year.
  • The "sub-optimal" vaccine is one cause of vaccine hesitancy, according to Adalja. "People extrapolate that to other vaccines, when this is truly specific to the problems we have with the flu vaccine. So, I do think that one of the most important tasks in infectious disease is to develop a universal flu vaccine because it would really move the threat from our biggest pandemic pathogen."
  • NIAID announced in 2017 that the vaccine was a priority.

What's happening: Multiple possible universal flu vaccines are in development, with several in trials now.

  • There's been success in mapping the flu virus to find better, more conserved parts of the virus that don't mutate as quickly and can be targeted by the vaccines, particularly using new technologies, Adalja says.
  • Mascola says the VRC is currently focused on attacking those targets through vaccines that use nanoparticles to allow the size, shape, and other properties to be more precisely controlled. These vaccines tend to be more safe and effective.
  • "We're really focused on vaccine constructs, vaccine antigens, vaccine platforms that could really improve what we have now toward the goal of making a vaccine that would be more universal — [with] broader, better, longer duration," Mascola says.
  • The VRC is working on different types of vaccines, targeting the whole hemagglutinin protein on the virus or just the stalk of that protein that doesn't change as much, he said. "If we could teach the immune system to generate antibodies to the stalk, that response could be a broader response, a more universal response, than the current licensed vaccines."
  • A universal flu vaccine will be the key to herd immunity to influenza, says Sarah Cobey, associate professor at the University of Chicago.

The latest: While trials of universal flu vaccines are ongoing and they don't have published results, Mascola says early human data is showing the vaccine focused on the stem is safe, well-tolerated and generated a "robust immune response" so far.

  • If the trial continues to progress there may be a universal flu vaccine available in five years, he said.
  • Adalja says while the current vaccines under development aren't "truly universal" because they don't cover 100% of the strains, he adds that they cover a broader range than current vaccines and "look promising."

The big picture: While the current pandemic has focused attention on the novel coronavirus, it also has re-upped interest in pandemic preparedness, particularly against a possible novel influenza strain, Cobey says.

  • And, some of the COVID-19 research on vaccine platforms, such as those for mRNA vaccines, could be used to create a better flu vaccine, she adds.

The bottom line: "If there was enough of a divergent strain of influenza that our existing immunity didn't recognize, you could have a severe influenza pandemic. That's the concern ... and this should be even more highlighted by the current COVID pandemic," Mascola says.

Go deeper:

Go deeper

Oct 16, 2020 - Podcasts

Operation Warp Speed's Moncef Slaoui on the new vaccine timeline

Pfizer today said it won't apply for an emergency use authorization for its COVID-19 vaccine until late November, all but guaranteeing that the FDA won't be asked to consider approval until after the election.

Axios Re:Cap goes deeper with Moncef Slaoui, the White House's top scientific advisor to Operation Warp Speed, the public-private partnership created to get a coronavirus vaccine deployed and developed.

Updated 2 mins ago - Energy & Environment

Thousands without power as "hazardous" winter storm lashes East Coast

Satellite imagery of the Northeastern U.S. taken by NOAA on Jan. 17. Photo: NOAA

A major winter storm lashed much of the East Coast Sunday and Monday, causing widespread power outages and disrupting travel over the holiday weekend.

The latest: Authorities in North Carolina confirmed that two people died in a car crash and that they responded 600 vehicle accidents during the storm on Sunday, per the Washington Post.

2 hours ago - Health

CDC director says COVID-19 messaging should have been clearer

Rochelle Walensky. Photo: Stefani Reynolds-Pool/Getty Images

Rochelle Walensky, director of the Centers for Disease Control and Prevention, said in an interview with the Wall Street Journal that the messaging around the COVID-19 pandemic and changing guidance should have been clearer.

State of play: Walensky is being coached by media experts and is planning to have more press briefings by herself in order to ensure that CDC is seen as an independent, scientific entity, rather than as a political one, the Journal reports.